Diabetes mellitus and congestive heart failure

Authors

DOI:

https://doi.org/10.22141/2224-0721.18.1.2022.1146

Keywords:

diabetes mellitus, congestive heart failure, review

Abstract

Congestive heart failure (CHF) is the final stage of cardiovascular disease and one of the leading causes of death. CHF develops in patients with the chronic coronary syndrome, hypertension, myocarditis, endocarditis, pericarditis, and other diseases. The prevalence of CHF in recent years is growing steadily and is about 2 % in the adult population. Among the factors that worsen the prognosis of CHF is diabetes mellitus (DM). Type 2 DM is an independent risk factor for heart failure (HF), and fasting plasma glucose and increased glycated hemoglobin A1c are significantly associated with an increased risk of HF. This review article summarizes the existing literature on the current state of the problem of DM and CHF. In particular, there are considered the issues related to the features of myocardial damage in type 2 DM, DM as a risk factor for HF, subclinical myocardial disorders in diabetic patients, HF as a risk factor for DM; pathophysiological features of DM and HF; classification of CHF (according to the New York Heart Association, the American College of Cardiology Foundation/American Heart Association, the European Society of Cardiology); diagnosis of CHF with preserved, reduced and mildly reduced left ventricular ejection fraction; principles of pathogenetic therapy of HF in DM, in particular, the appointment of drugs that affect the renin-angiotensin-aldosterone system (angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers); sacubitril/valsartan; beta-adrenergic receptor blockers, mineralocorticoid receptor antagonists, sinus node inhibitors, sodium-glucose cotransporter type 2 inhibitors, diuretics. Treatment of a patient with DM and HF will be successful only if adequate and safe antidiabetic therapy is prescribed, on the one hand, and metabolically neutral pharmacological therapy, on the other.

Downloads

Download data is not yet available.

References

Lawson CA, Jones PW, Teece L, et al. Association Between Type 2 Diabetes and All-Cause Hospitalization and Mortality in the UK General Heart Failure Population: Stratification by Diabetic Glycemic Control and Medication Intensification. JACC Heart Fail. 2018 Jan;6(1):18-26. doi:10.1016/j.jchf.2017.08.020.

Dei Cas A, Khan SS, Butler J, et al. Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. JACC Heart Fail. 2015 Feb;3(2):136-145. doi:10.1016/j.jchf.2014.08.004.

Kristensen SL, Preiss D, Jhund PS, et al. Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circ Heart Fail. 2016 Jan;9(1):e002560. doi:10.1161/CIRCHEARTFAILURE.115.002560.

Serhiyenko VA, Serhiyenko AA. Diabetic cardiomyopathy: epidemiology, etiology and pathogenesis. Mìžnarodnij endokrinologìčnij žurnal. 2020;16(4):337-348. doi:10.22141/2224-0721.16.4.2020.208488. (in Ukrainian).

Koval SM, Yushko KO, Snihurska IO, et al. Relations of angiotensin-(1-7) with hemodynamic and cardiac structural and functional parameters in patients with hypertension and type 2 diabetes. Arterial Hypertension. 2019;23(3):183-189. doi:10.5603/AH.a2019.0012.

Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation. 2019 Aug 13;140(7):e294-e324. doi:10.1161/CIR.0000000000000691.

Shah AD, Langenberg C, Rapsomaniki E, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people. Lancet Diabetes Endocrinol. 2015 Feb;3(2):105-113. doi:10.1016/S2213-8587(14)70219-0.

Kobalava ZD, Medovchshikov VV, Yeshniyazov NB, Khasanova ER. The modern paradigm of pathophysiology, prevention and treatment of heart failure in type 2 diabetes mellitus. Russian Journal of Cardiology. 2019;(11):98-111. doi:10.15829/1560-4071-2019-11-98-111. (in Russian).

Mardanov BU, Korneeva MN, Akhmedova EB. Heart failure and diabetes mellitus: selected issues of etiology and pathogenesis, prognosis and treatment. Rational Pharmacotherapy in Cardiology. 2016;12(6):743-748. doi:10.20996/1819-6446-2016-12-6-743-748. (in Russian).

Levelt E, Mahmod M, Piechnik SK, et al. Relationship between left ventricular structural and metabolic remodeling in type 2 diabetes. Diabetes. 2016 Jan;65(1):44-52. doi:10.2337/db15-0627.

Levelt E, Rodgers CT, Clarke WT, et al. Cardiac energetics, oxygenation, and perfusion during increased workload in patients with type 2 diabetes mellitus. Eur Heart J. 2016 Dec 7;37(46):3461-3469. doi:10.1093/eurheartj/ehv442.

Obrezan AG, Kulikov NV. Chronic heart failure and diabetes mellitus: pathogenesis and possibilities of treatment. Kardiologiia. 2018;58(7):85-94. doi:10.18087/cardio.2018.7.10156. (in Russian).

Montaigne D, Marechal X, Coisne A, et al. Myocardial contractile dysfunction is associated with impaired mitochondrial function and dynamics in type 2 diabetic but not in obese patients. Circulation. 2014 Aug 12;130(7):554-564. doi:10.1161/CIRCULATIONAHA.113.008476.

Boonman-de Winter LJ, Rutten FH, Cramer MJ, et al. Efficiently screening heart failure in patients with type 2 diabetes. Eur J Heart Fail. 2015 Feb;17(2):187-195. doi:10.1002/ejhf.216.

Zoppini G, Bergamini C, Bonapace S, et al. Association between subclinical left ventricular systolic dysfunction and glycemic control in asymptomatic type 2 diabetic patients with preserved left ventricular function. J Diabetes Complications. 2017 Jun;31(6):1035-1040. doi:10.1016/j.jdiacomp.2017.01.021.

Selvin E, Lazo M, Chen Y, et al. Diabetes mellitus, prediabetes, and incidence of subclinical myocardial damage. Circulation. 2014 Oct 14;130(16):1374-1382. doi:10.1161/CIRCULATIONAHA.114.010815.

Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014 Oct 28;130(18):1579-1588. doi:10.1161/CIRCULATIONAHA.114.010389.

Swoboda PP, McDiarmid AK, Erhayiem B, et al. Diabetes mellitus, microalbuminuria, and subclinical cardiac disease: identification and monitoring of individuals at risk of heart failure. J Am Heart Assoc. 2017 Jul 17;6(7):e005539. doi:10.1161/JAHA.117.005539.

Paolillo S, Rengo G, Pellegrino T, et al. Insulin resistance is associated with impaired cardiac sympathetic innervation in patients with heart failure. Eur Heart J Cardiovasc Imaging. 2015 Oct;16(10):1148-1153. doi:10.1093/ehjci/jev061.

Campbell P, Krim S, Ventura H. The bi-directional impact of two chronic illnesses: heart failure and diabetes - A review of the epidemiology and outcomes. Card Fail Rev. 2015 Apr;1(1):8-10. doi:10.15420/cfr.2015.01.01.8.

Preiss D, van Veldhuisen DJ, Sattar N, et al. Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail. 2012 Aug;14(8):909-915. doi:10.1093/eurjhf/hfs067.

Marwick TH, Ritchie R, Shaw JE, Kaye D. Implications of Underlying Mechanisms for the Recognition and Management of Diabetic Cardiomyopathy. J Am Coll Cardiol. 2018 Jan 23;71(3):339-351. doi:10.1016/j.jacc.2017.11.019.

Veklich AS, Koziolova NA, Karavaev PG. Cardiovascular remodeling in patients with diabetic сardiomyopathy. Russian Journal of Cardiology. 2019;(11):42-47. doi:10.15829/1560-4071-2019-11-42-47. (in Russian).

Serhiyenko VA, Serhiyenko AA. Diabetic cardiomyopathy: classification, instrumental diagnostic methods. Mìžnarodnij endokrinologìčnij žurnal. 2020;16(7):577-587. doi:10.22141/2224-0721.16.7.2020.219012. (in Ukrainian).

Bonapace S, Valbusa F, Bertolini L, et al. Early impairment in left ventricular longitudinal systolic function is associated with an increased risk of incident atrial fibrillation in patients with type 2 diabetes. J Diabetes Complications. 2017 Feb;31(2):413-418. doi:10.1016/j.jdiacomp.2016.10.032.

Waddingham MT, Edgley AJ, Tsuchimochi H, Kelly DJ, Shirai M, Pearson JT. Contractile apparatus dysfunction early in the pathophysiology of diabetic cardiomyopathy. World J Diabetes. 2015 Jul 10;6(7):943-960. doi:10.4239/wjd.v6.i7.943.

MacRae CA. The genetics of congestive heart failure. Heart Fail Clin. 2010 Apr;6(2):223-230. doi:10.1016/j.hfc.2009.11.004.

Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Oct 15;62(16):e147-239. doi:10.1016/j.jacc.2013.05.019.

Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 Jul 14;37(27):2129-2200. doi:10.1093/eurheartj/ehw128.

Fillmore N, Mori J, Lopaschuk GD. Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy. Br J Pharmacol. 2014 Apr;171(8):2080-2090. doi:10.1111/bph.12475.

Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation. 2017 Jul 4;136(1):6-19. doi:10.1161/CIRCULATIONAHA.116.026807.

Riehle C, Abel ED. Insulin signaling and heart failure. Circ Res. 2016 Apr 1;118(7):1151-1169. doi:10.1161/CIRCRESAHA.116.306206.

Zoroufian A, Razmi T, Taghavi-Shavazi M, Lotfi-Tokaldany M, Jalali A. Evaluation of subclinical left ventricular dysfunction in diabetic patients: longitudinal strain velocities and left ventricular dyssynchrony by two-dimensional speckle tracking echocardiography study. Echocardiography. 2014 Apr;31(4):456-63. doi:10.1111/echo.12389.

Leung M, Wong VW, Hudson M, Leung DY. Impact of Improved Glycemic Control on Cardiac Function in Type 2 Diabetes Mellitus. Circ Cardiovasc Imaging. 2016 Mar;9(3):e003643. doi:10.1161/CIRCIMAGING.115.003643.

Seferovic JP, Claggett B, Seidelmann SB, et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017 May;5(5):333-340. doi:10.1016/S2213-8587(17)30087-6.

Ofstad AP, Atar D, Gullestad L, Langslet G, Johansen OE. The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions. Heart Fail Rev. 2018 May;23(3):303-323. doi:10.1007/s10741-018-9685-0.

Komamura K. Similarities and differences between the pathogenesis and pathophysiology of diastolic and systolic heart failure. Cardiol Res Pract. 2013;2013:824135. doi:10.1155/2013/824135.

Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 Jul 14;37(27):2129-2200. doi:10.1093/eurheartj/ehw128.

Skybchyk VA. Chronic heart failure: new approaches to diagnosis and treatment. Liki Ukr. 2016;(206):33-42. (in Ukrainian).

Oudejans I, Mosterd A, Bloemen JA, et al. Clinical evaluation of geriatric outpatients with suspected heart failure: value of symptoms, signs, and additional tests. Eur J Heart Fail. 2011 May;13(5):518-527. doi:10.1093/eurjhf/hfr021.

Van Riet EE, Hoes AW, Limburg A, Landman MA, van der Hoeven H, Rutten FH. Prevalence of unrecognized heart failure in older persons with shortness of breath on exertion. Eur J Heart Fail. 2014 Jul;16(7):772-777. doi:10.1002/ejhf.110.

Wong CM, Hawkins NM, Petrie MC, et al. Heart failure in younger patients: the Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). Eur Heart J. 2014 Oct 14;35(39):2714-2721. doi:10.1093/eurheartj/ehu216.

Voronkov LG, Amosova KM, Dzjak GV, et al. Recommendations of the Association of Cardiologists of Ukraine for the diagnosis and treatment of chronic heart failure (2017). Serceva nedostatnist' ta komorbidni stany. 2017;(Suppl 1):1-64. (in Ukrainian).

Russian Society of Cardiology; National Society for the Study of Heart Failure and Myocardial Diseases; Society of Heart Failure Specialists. Khronicheskaia serdechnaia nedostatochnost': klinicheskie rekomendatsii [Chronic heart failure: clinical practice guidelines]. Irkutsk; 2020. 183 p. (in Russian).

Berliner D, Hänselmann A, Bauersachs J. The Treatment of Heart Failure with Reduced Ejection Fraction. Dtsch Arztebl Int. 2020 May 22;117(21):376-386. doi:10.3238/arztebl.2020.0376.

Strauss MH, Hall AS. The Divergent Cardiovascular Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Blockers in Adult Patients with Type 2 Diabetes Mellitus. Can J Diabetes. 2018 Apr;42(2):124-129. doi:10.1016/j.jcjd.2017.09.011.

Lam PH, Dooley DJ, Fonarow GC, et al. Similar clinical benefits from below-target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial. Eur J Heart Fail. 2018 Feb;20(2):359-369. doi:10.1002/ejhf.937.

Cheng J, Zhang W, Zhang X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med. 2014 May;174(5):773-785. doi:10.1001/jamainternmed.2014.348.

Seferovic PM, Ponikowski P, Anker SD, et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019 Oct;21(10):1169-1186. doi:10.1002/ejhf.1531.

McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep 11;371(11):993-1004. doi:10.1056/NEJMoa1409077.

Packer M, Anker SD, Butler J, et al. Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. Eur Heart J. 2021 Feb 11;42(6):671-680. doi:10.1093/eurheartj/ehaa968.

Connelly KA, Gilbert RE, Liu P; Diabetes Canada Clinical Practice Guidelines Expert Committee. Treatment of diabetes in people with heart failure. Can J Diabetes. 2018 Apr;42(Suppl 1):S196-S200. doi:10.1016/j.jcjd.2017.10.026.

Torp-Pedersen C, Metra M, Charlesworth A, et al. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart. 2007 Aug;93(8):968-973. doi:10.1136/hrt.2006.092379.

Casiglia E, Tikhonoff V. Long-standing problem of β-blocker-elicited hypoglycemia in diabetes mellitus. Hypertension. 2017 Jul;70(1):42-43. doi:10.1161/HYPERTENSIONAHA.117.09378.

Dungan K, Merrill J, Long C, Binkley P. Effect of beta blocker use and type on hypoglycemia risk among hospitalized insulin requiring patients. Cardiovasc Diabetol. 2019 Nov 27;18(1):163. doi:10.1186/s12933-019-0967-1.

Kosmas CE, Silverio D, Sourlas A, Montan PD, Guzman E. Role of spironolactone in the treatment of heart failure with preserved ejection fraction. Ann Transl Med. 2018 Dec;6(23):461. doi:10.21037/atm.2018.11.16.

Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011 Jan 6;364(1):11-21. doi:10.1056/NEJMoa1009492.

Pitt B, Anker SD, Böhm M, et al. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. Eur J Heart Fail. 2015 Feb;17(2):224-232. doi:10.1002/ejhf.218.

Paneni F. Empagliflozin across the stages of diabetic heart disease. Eur Heart J. 2018 Feb 1;39(5):371-373. doi:10.1093/eurheartj/ehx519.

Van Melle JP, Bot M, de Jonge P, de Boer RA, van Veldhuisen DJ, Whooley MA. Diabetes, glycemic control, and new-onset heart failure in patients with stable coronary artery disease: data from the heart and soul study. Diabetes Care. 2010 Sep;33(9):2084-2089. doi:10.2337/dc10-0286.

Published

2022-06-29

How to Cite

Serhiyenko, V., & Serhiyenko, A. (2022). Diabetes mellitus and congestive heart failure. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), 18(1), 57–69. https://doi.org/10.22141/2224-0721.18.1.2022.1146

Issue

Section

Literature Review

Most read articles by the same author(s)